vivli web-based data request platform (AstraZeneca ltd)
90
Structured Review
AstraZeneca ltd
vivli web-based data request platform
Vivli Web Based Data Request Platform, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/web-based+data+platform/vivli+member+page/pm40025003-387-30-39
Average 90 stars, based on 1 article reviews
Vivli Web Based Data Request Platform, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/web-based+data+platform/vivli+member+page/pm40025003-387-30-39
Average 90 stars, based on 1 article reviews
vivli web-based data request platform - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Derivative Assay:Article Title: Overcoming Barriers to Remission in Severe Eosinophilic Asthma: Two-Year Real-World Data With Benralizumab. Article Snippet: Article Title: Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study Article Snippet: The AstraZeneca Vivli member page is also available, outlining further details: https://vivli.org/ourmember/astrazeneca/ (accessed on 23 October 2023). Article Title: Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Article Snippet: George Lau, Ghassan K. Abou-Alfa, Ann-Lii Cheng, Wattana Sukeepaisarnjaroen, Tu Van Dao, Yoon Koo Kang, Satheesh Chiradoni Thungappa, Masatoshi Kudo, Bruno Sangro, Robin Kate Kelley, Junji Furuse, Joong-Won Park, Patrapim Sunpaweravong, Angelica Fasolo, Thomas Yau, Tomokazu Kawaoka, Sergio Azevedo, Maria Reig, Eric Assenat, Mark Yarchoan, Aiwu Ruth He, Mallory Makowsky, Charu Gupta, Alejandra Negro, Stephen L. Chan Article Title: Pretrained transformers applied to clinical studies improve predictions of treatment efficacy and associated biomarkers. Article Snippet: AstraZeneca group of companies allows researchers to submit a request to access anonymized patient-level clinical data, aggregated clinical or genomics data (when available), and/or anonymized clinical study documents through the Vivli (https://vivli.org) web-based data request platform, in accordance with Article Title: Pretrained transformers applied to clinical studies improve predictions of treatment efficacy and associated biomarkers Article Snippet: AstraZeneca group of companies allows researchers to submit a request to access anonymized patient-level clinical data, aggregated clinical or genomics data (when available), and/or anonymized clinical study documents through the Vivli ( https://vivli.org ) web-based data request platform, in accordance with Article Title: iPREDICT: proof-of-concept study to develop a predictive model of changes in asthma control Article Snippet: Article Title: Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial Article Snippet: Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, PA, USA (G Haidar MD); Biometrics (S Thomas MS), Vaccines & Immune Therapies (S Thomas, A A Aksyuk PhD, J L Perez MD, L-J Chang MD, T S Cohen PhD), and Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences (L E Clegg PhD; H Yang PhD), BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA; Chiesi USA, Cary, NC, USA (S Thomas); Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Cambridge, UK (M Gibbs PhD, A Currie MSc); Service des Maladies Infectieuses et Tropicales, CHU Nîmes Carémeau, Université de Montpellier, Nîmes, France (Prof P Loubet MD); Western Australia Centre for Thrombosis and Haemostasis, Murdoch University, Perth, WA, Australia (Prof R I Baker MBBS); Clinical Research Unit, Perth Blood Institute, Perth, WA, Australia (Prof R I Baker); Hollywood Hospital Haemophilia Centre, Haematology Academic Unit, Perth, WA, Australia (Prof R I Baker); Department of Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial Article Title: Machine learning modeling of patient health signals informs long-term survival on immune checkpoint inhibitor therapy Article Snippet: The AstraZeneca group of companies allows researchers to submit a request to access anonymized patient-level clinical data, aggregated clinical or genomics data (when available), and/or anonymized clinical study documents through the Vivli ( https://vivli.org ) web-based data request platform, in accordance with Diagnostic Assay:Article Title: Overcoming Barriers to Remission in Severe Eosinophilic Asthma: Two-Year Real-World Data With Benralizumab. Article Snippet: Article Title: Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study Article Snippet: The AstraZeneca Vivli member page is also available, outlining further details: https://vivli.org/ourmember/astrazeneca/ (accessed on 23 October 2023). Article Title: Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Article Snippet: George Lau, Ghassan K. Abou-Alfa, Ann-Lii Cheng, Wattana Sukeepaisarnjaroen, Tu Van Dao, Yoon Koo Kang, Satheesh Chiradoni Thungappa, Masatoshi Kudo, Bruno Sangro, Robin Kate Kelley, Junji Furuse, Joong-Won Park, Patrapim Sunpaweravong, Angelica Fasolo, Thomas Yau, Tomokazu Kawaoka, Sergio Azevedo, Maria Reig, Eric Assenat, Mark Yarchoan, Aiwu Ruth He, Mallory Makowsky, Charu Gupta, Alejandra Negro, Stephen L. Chan Article Title: Pretrained transformers applied to clinical studies improve predictions of treatment efficacy and associated biomarkers. Article Snippet: AstraZeneca group of companies allows researchers to submit a request to access anonymized patient-level clinical data, aggregated clinical or genomics data (when available), and/or anonymized clinical study documents through the Vivli (https://vivli.org) web-based data request platform, in accordance with Article Title: Pretrained transformers applied to clinical studies improve predictions of treatment efficacy and associated biomarkers Article Snippet: AstraZeneca group of companies allows researchers to submit a request to access anonymized patient-level clinical data, aggregated clinical or genomics data (when available), and/or anonymized clinical study documents through the Vivli ( https://vivli.org ) web-based data request platform, in accordance with Article Title: iPREDICT: proof-of-concept study to develop a predictive model of changes in asthma control Article Snippet: Article Title: Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial Article Snippet: Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, PA, USA (G Haidar MD); Biometrics (S Thomas MS), Vaccines & Immune Therapies (S Thomas, A A Aksyuk PhD, J L Perez MD, L-J Chang MD, T S Cohen PhD), and Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences (L E Clegg PhD; H Yang PhD), BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA; Chiesi USA, Cary, NC, USA (S Thomas); Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Cambridge, UK (M Gibbs PhD, A Currie MSc); Service des Maladies Infectieuses et Tropicales, CHU Nîmes Carémeau, Université de Montpellier, Nîmes, France (Prof P Loubet MD); Western Australia Centre for Thrombosis and Haemostasis, Murdoch University, Perth, WA, Australia (Prof R I Baker MBBS); Clinical Research Unit, Perth Blood Institute, Perth, WA, Australia (Prof R I Baker); Hollywood Hospital Haemophilia Centre, Haematology Academic Unit, Perth, WA, Australia (Prof R I Baker); Department of Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial Article Title: Machine learning modeling of patient health signals informs long-term survival on immune checkpoint inhibitor therapy Article Snippet: The AstraZeneca group of companies allows researchers to submit a request to access anonymized patient-level clinical data, aggregated clinical or genomics data (when available), and/or anonymized clinical study documents through the Vivli ( https://vivli.org ) web-based data request platform, in accordance with |